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Background: Central disinhibition is a mechanism involved in the physiopathology of fibromyalgia. Melatonin
can improve sleep quality, pain and pain threshold. We hypothesized that treatment with melatonin alone or
in combination with amitriptyline would be superior to amitriptyline alone in modifying the endogenous
pain-modulating system (PMS) as quantified by conditional pain modulation (CPM), and this change in CPM could
be associated with serum brain-derived neurotrophic factor (BDNF). We also tested whether melatonin improves
the clinical symptoms of pain, pain threshold and sleep quality.
Methods: Sixty-three females, aged 18 to 65, were randomized to receive bedtime amitriptyline (25 mg) (n = 21),
melatonin (10 mg) (n = 21) or melatonin (10 mg) + amitriptyline (25 mg) (n = 21) for a period of six weeks. The
descending PMS was assessed with the CPM-TASK. It was assessed the pain score on the Visual Analog Scale (VAS
0-100 mm), the score on Fibromyalgia Impact Questionnaire (FIQ), heat pain threshold (HPT), sleep quality and
BDNF serum. Delta values (post- minus pre-treatment) were used to compare the treatment effect. The outcomes
variables were collected before, one and six weeks after initiating treatment.
Results: Melatonin alone or in combination with amitriptyline reduced significantly pain on the VAS compared
with amitriptyline alone (P < 0.01). The delta values on the VAS scores were-12.85 (19.93),-17.37 (18.69) and-20.93
(12.23) in the amitriptyline, melatonin and melatonin+amitriptyline groups, respectively. Melatonin alone and in
combination increased the inhibitory PMS as assessed by the Numerical Pain Scale [NPS(0-10)] reduction during
the CPM-TASK:-2.4 (2.04) melatonin + amitriptyline,-2.65 (1.68) melatonin, and-1.04 (2.06) amitriptyline, (P < 0.05).
Melatonin + amitriptyline treated displayed better results than melatonin and amitriptyline alone in terms of FIQ
and PPT improvement (P < 0.05, fort both).
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Conclusion: Melatonin increased the inhibitory endogenous pain-modulating system as assessed by the reduction
on NPS(0-10) during the CPM-TASK. Melatonin alone or associated with amitriptyline was better than amitriptyline
alone in improving pain on the VAS, whereas its association with amitriptyline produced only marginal additional
clinical effects on FIQ and PPT.
Trial registration: Current controlled trail is registered at clinical trials.gov upon under number NCT02041455.
Registered January 16, 2014.
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Fibromyalgia (FM) is a syndrome characterized by chronic
widespread musculoskeletal pain, hyperalgesia, allodynia,
stiffness of the body, fatigue, sleep disorders, circadian
rhythm disturbances, anxiety, depression and, commonly,
a high level of catastrophizing related to pain [1,2]. A pre-
vious study demonstrated that patients with fibromyalgia
have low melatonin secretion, which could explain the
lack of restorative sleep [3], which is a predisposing
factor in trigger point formation [4] and dysfunction of
pain modulation mechanisms [3]. Melatonin can block
the cycle of impaired sleep at night, fatigue during the day
[5-7], and can induce circadian rhythm synchronization
[8]. In addition, melatonin administration in mice has
antidepressant effects [9] and, in humans, anxiolytic prop-
erties [10].
Melatonin’s effect on pain has been demonstrated in an-
imals for inflammatory [8] and neuropathic pain [11-13],
as well in acute [10,14] and chronic pain in humans
[15,16]. In addition, there is some clinical evidence of mel-
atonin’s effect on FM [5,6]. However, the various study re-
sults are not consistent, possibly because the dose used
has been low (3-5 mg). In regard to the melatonin dose
for pain, a recent randomized clinical trial (RCT) indi-
cated that 10 mg at bedtime produced a large size effect
for chronic pelvic pain [16]. In addition, melatonin re-
duced the BDNF serum level in patients with chronic pel-
vic pain induced by endometriosis [16].
Pain is a dynamic phenomenon resulting from the ac-
tivity of both endogenous pain excitatory and inhibitory
systems, including inhibitory conditioned pain modula-
tion (ICPM) [17]. The efficacy of ICPM in FM has been
related to sleep quality [18]. This relationship is supported
on neurobiological grounds by common neurotransmit-
ters involved in both sleep and ICPM, including noradren-
alin (NA), serotonin (5-HT) and dopamine (DA) [19-22].
Thus, it is important to investigate the therapeutic effect
of drugs such as melatonin that present multifaceted
mechanisms that may interfere in the peripheral and cen-
tral pain mechanisms. The rationale that supports this hy-
pothesis consists of evidence that, in long-term chronic
pain situations, there is a loss of inhibitory system func-
tion, as demonstrated in FM by the pain threshold andconditioned pain modulation (CPM) [23]. Accordingly, in
a recent study, we demonstrated that long-term muscu-
loskeletal pain occurs with excessive cortical facilitation
(a lack of inhibition), which is associated with lower pain
threshold and higher levels of catastrophizing thinking
related to pain [24]. In addition, numerous pre-clinical
studies have demonstrated that ICPM depends on the
recruitment of endogenous opioids in the periaqueductal
gray, which trigger the release of 5-HT from neurons
localized in the raphe nuclei (medulla), which, in turn,
dampens nociceptive afferents at the dorsal horn of the
spinal cord [25]. Noradrenergic projections from the locus
coeruleus produce similar effects [25]. Together, this
evidence justifies assessing the effect of melatonin in the
descending modulatory pain systems, alone or combined
with classic therapeutic agents such as amitriptyline, as it
has been demonstrated that melatonin increases the pain
threshold in healthy subjects [26], improves sleep quality
[15] and modulates systems involved in pain, such as the
GABAergic and opioidergic systems [12,27,28].
Taking all of this information into account, we hypoth-
esized that melatonin treatment alone or in combination
with amitriptyline is better than amitriptyline alone at
modifying the endogenous pain-modulating system. Thus,
to prove our hypothesis, in this study, we quantified the
conditioned pain modulation (CPM)-TASK, as well BDNF
serum levels in FM patients who received melatonin treat-
ment alone or in combination with amitriptyline. We also
tested whether melatonin improved clinical symptoms
such as pain, pain threshold (PPT) and sleep quality
related to fibromyalgia.
Methods
The Methods and Results sections are reported according
to the CONSORT guidelines [29]. Figure 1 shows the flow
chart of the study.
Design overview, setting, and participants
All patients provided written informed consent before
participating in this randomized, double-blind, double-
dummy, three-group parallel, clinical trial, which was
approved by the Research Ethics Committee at the Hos-
pital de Clínicas de Porto Alegre (HCPA) (Institutional
Figure 1 Flow chart showing recruitment and progress through the study. FMS: fibromyalgia syndrome; FIQ: fibromyalgia impact
questionnaire; PPT: pain pressure threshold; QST: quantitative sensory testing; SCID: Structured Clinical Interview for DSM-IV; pain VAS: visual
analog scale of pain; major side effects (MJSE) (severe dizziness, vivid nightmares, crippling drowsiness, severe headache, behavioral changes, and
pain worsening).
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laration of Helsinki (Resolution 196/96 of the National
Health Council). We included 63 adult patients aged 18-
years-old or older from among the pain and physiatrist
clinical outpatients of the HCPA and via newspaper
publicity. Patients with FM were enrolled according to
American College of Rheumatology criteria [30]. To be
eligible, patients had to be refractory to their current
treatment. Patients were required to have a score of at
least 50 mm on the 0-100 mm visual analogue scale
(VAS, which 0 means “no pain” and 100 means “worst
possible pain”) [31] during the baseline week preceding
randomization and to have completed at least four pain
diaries out of seven. Patients were allowed to remain on
analgesic medications, including drugs for which they
were refractory, and these medications could not be
adjusted during the study. At screening, all patients
underwent physical examination by a pain specialist and
a psychiatric interview with a psychiatrist. Patients could
enroll with or without a history of major depressivedisorder; however, it could not be the main reason for
their functional impairment or study enrollment. Sub-
jects were recruited solely for fibromyalgia pain. Patients
were excluded if evidence was found of inflammatory
rheumatic disease, autoimmune disease or other painful
disorders that might confound the assessment of fibro-
myalgia pain or a history of substance abuse. Patients
who were pregnant, breast-feeding or had a history of
neurologic or oncologic disease, ischemic heart disease,
kidney or hepatic insufficiency were also excluded.
Sample size justification
The number of patients in each study group was deter-
mined by previous clinical trials [32]. An a priori esti-
mate indicated that a total sample size of 57 patients
divided into three balanced treatment groups (n = 19)
was needed to detect a 1.4-cm reduction (average stand-
ard deviation 1.2 cm) in pain intensity associated with
melatonin or placebo at power and α levels of 0.8 and
0.01, respectively [33]; such a reduction would be clinically
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ventions. To account for multiple outcomes and attrition,
we increased the sample size to 21 patients per group. For
these calculations, we assumed that this remission was
clinically relevant.
Randomization and masking
The participants were randomized into one of three
groups: amitriptyline (+placebo), melatonin (+placebo),
and amitriptyline + melatonin. Before the recruitment
phase, envelopes containing the protocol materials
were prepared. Each envelope was sealed and num-
bered sequentially and contained an allocated treat-
ment. After the participant consented to participate in
the trial, in the sequence, the nurse, who administered
the medications, opened the envelope. During the en-
tire protocol timeline, two investigators who were not
involved in patient evaluations were responsible for
the blinding and randomization procedures. Other in-
dividuals who were involved in patient care were un-
aware of the treatment group to which the patients
belonged.
Interventions
Over a six-week period (42 days), the following oral
medications were taken at bedtime by the three groups:
melatonin (10 mg) tablets + placebo (Sigma Chemical,
Germany, provided batch-by-batch certificates of analysis
authenticating the purity of each batch), amitriptyline
(25 mg) + placebo or amitriptyline (25 mg) +melatonin
(10 mg) with identical characteristics. The capsules were
manufactured in such a way that the placebo and active
treatment had the same size, color, smell and flavor. To
measure adherence to medication use, we employed the
following strategies: i) a researcher counted the number of
tablets consumed weekly during the study period; ii) the
patients were asked to record a diary entry if they failed to
use the medication; iii) eligible patients were strongly en-
couraged to remain on the medication throughout the six
weeks, during which time they visited the clinical center
the third week after beginning the treatment. Regardless
of their decision to continue or discontinue medication at
this stage, the patients continued to be assessed during
the study period.
Supplementary analgesic use
All of the patients were permitted to use supplementary
analgesic medication (acetaminophen, ibuprofen, codeine
or tramadol) to relieve their pain if necessary. Patients were
allowed to take 750 mg of acetaminophen up to four times
per day (QID) and 200 mg of ibuprofen at maximum QID
as a rescue analgesic. If their pain persisted, patients could
use Dorflex® (Sanofi Aventis, São Paulo, Brazil; 35 mg of
orfenadrine citrate combined with 300 mg of dypirone and50 mg of caffeine). If their pain persisted, patients were
permitted to use 60 mg of codeine up to QID or tramadol
three times per day (TID). These medications could be
used a maximum of four times a day. The patients were
asked to record their analgesic intake during the treatment
period in their diaries, and these diaries were reviewed at
the end of the treatment section. The total analgesic dose
taken during the last week of treatment was considered for
the analysis.
Instruments and assessments
All of the psychological tests used in this study have
been validated for the Brazilian population [34,35]. Two
independent medical examiners that were blind to the
group assignments were trained to administer the pain
scales and conduct the psychological tests. The baseline
depressive symptoms of the patients were assessed using
the Hamilton Depression Scale [35], and sleep quality
was assessed using the Pittsburgh Sleep Quality Index
[36]. Psychiatric disorders were evaluated with the
Structured Clinical Interview for DSM-IV Axis I Disor-
ders (SCID-I) [37]. To assess catastrophic thinking due
to chronic pain, we used the B-PCS [38]. Demographic
data and medical comorbidities were assessed using a
standardized questionnaire; patients were asked about
any changes that occurred during treatment, such as
changes in mood, sleepiness, dizziness, headaches or al-
lergic reactions.
Outcomes
The primary outcomes were pain score diaries on the
Visual Analog Scale (VAS) [global pain in the last
24 hours] obtained during the last week of treatment and
pain reduction on the Numerical Pain Scale [NPS(0-10)]
during the CPM-TASK. The secondary outcomes were
the amount of analgesics used in the last week of treat-
ment, the score on Fibromyalgia Impact Questionnaire
(FIQ), Pressure Pain Thresholds (PPT), sleep quality and
BDNF serum levels. The outcomes are described below.
Assessment of pain and sleep quality
a) The pain intensity was measured with a 100-mm
VAS. The VAS scores ranged from no pain (zero)
to worst possible pain (100 mm). The time of the
worst pain during the last 24 h was recorded daily
in the patients’ diaries obtained at baseline during
the seven days before beginning the treatment and
the last week of the treatment period. They were
asked to answer the following question using the
pain VAS: i) considering your pain, how intense
was your worst pain during the last 24 hours? Diary
entries recorded analgesic intake (acetaminophen,
non-steroidal anti-inflammatory drugs (NSAIDs)
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the last week of treatment was considered for
analysis.
b) The quality of life of the patients in this study was
evaluated using the Fibromyalgia Impact Question-
naire (FIQ), a disease-specific questionnaire initially
proposed by Burckhardt et al. [39] for the evaluation
of quality of life in patients with fibromyalgia. It was
validated for use in the Brazilian population by
Marques et al. [40]. This questionnaire is composed
of 10 domains, the first consisting of 10 sub-items or
questions, and the other nine of only one question
each. The first domain contains questions concern-
ing the capacity of the patient to perform certain
routine activities. Responses range from 0, always
able to perform the activity, to 3, never able to
perform the activity. Item two refers to the number
of days during that the patient felt well in the
previous week, and item three refers to the number
of days that the patient was unable to go to work
because of the disease. Possible answers range from
0 to 7 for each item or domain. For domains 4-10,
the scores range from 0 to 10 in each. These final
seven items are designed to collect data on the
patient’s capacity to work and their perceptions of
pain, fatigue, morning stiffness, mood, anxiety and
depression. The data from the FIQ are arranged so
that no more than 10 points can be scored for any
single item. Items 2 and 3 are considered inversely
proportional; therefore, the maximum possible score
in this questionnaire will generally be 100.
c) Sleep quality during the study period was assessed
using the Pittsburgh Sleep Quality Index [36].
Assessment of PPT and conditioned pain modulation
a) Pressure pain thresholds (PPT alone): Prior to the
test trial, the patient learned to differentiate the
perception of pressure versus the perception of the
onset of pain. The patient was instructed to ver-
bally report the perception of pain onset. The in-
vestigator who assessed pain threshold levels was
trained, blinded to the intervention and unable
to view the display of pressure intensities. An
experienced rehabilitation physician (SAZ) system-
atically evaluated superficial and deep hyperalgesia
by assessing PPT using an algometer [41]. The de-
vice had a 1-cm2 hard-rubber probe, which was
applied over eleven predefined different areas to
define the PPT. These areas are among the nine-
teen areas corresponding to the diagnosis of
FM according to the American College of
Rheumatology criteria [30]. We determined the in-
dividual’s PPT using the area that presented thelowest PPT. The average values of PPT in kgf/cm2
(lb/cm2) for three successive readings taken at in-
tervals of 3-5 min were used as the outcomes.
b) To test CPM (the term CPM rather than diffuse
noxious inhibitory control [DNIC] is chosen based
on the recent recommendations of Yarnitsky et al.
[17]), we used the protocol of Tousignant-Laflamme
[42] and consulted the guidelines for the cold-heat
task (CPM-TASK) as an experimental pain stimulus
[43]. The CPM-TASK activates the diffuse noxious
inhibitory control-like effect (CPM), as it is a strong
nociceptive stimulus that takes place over a lengthy
span of time [44] and is applied over a large body
surface area [45]. Thus, the CPM-TASK allows us to
modify the endogenous pain-modulating system. To
quantify CPM, we evaluated the pain intensity of
three heat pain (HPT) test stimuli separated by a
CPM-TASK. Even if the HPT may lead to both ha-
bituation and sensitization according to the dual
process theory, the cold water zero is a reliable
stimulus to induce CPM [42].
c) CPM-Task: The cold-heat task was used as a con-
ditioning stimulus to elicit a strong and prolonged
pain sensation to trigger CPM. The CPM-TASK
consisted of immersing the non-dominant hand
cold water (zero to 1°C) for 1 minute. During the
last 30 seconds of cold-water immersion, the HPT
procedure was administered over the right forearm
(dominant forearm). The temperature was held
constant during the experiment for each subject.
The mean temperature eliciting pain ratings of 0/
10 on the Numerical Pain Scale [(NPS)0-10] (HPT)
was used for the HPT. After a short break, the
first HPT (Pain baseline, HPT0) was applied at the
extensor carpi radialis longus muscle (forearm) of
the dominant forearm. Following the first HPT
(HPT0), the CPM-TASK was used to trigger CPM.
One minute after the CPM-TASK, we applied the
second HPT (HPT1). We quantified the amount
of CPM by subtracting the mean pain rating of
the second HPT after the CPM-TASK (HPT1)
from the first HPT before the CPM-TASK (HPT1)
[46].
d) Laboratory outcomes included serum levels of
BDNF. Samples of blood were collected at two time
points: at baseline and at the end of treatment. The
blood samples were centrifuged in plastic tubes
for 10 min at 4500 × g at 4°C, and serum was stored
at-80 °C for assay. Serum BDNF was determined by
the Enzyme-Linked Immunosorbent Assay (ELISA)
using a ChemiKine BDNF Sandwich ELISA Kit,
CYT306 (Chemicon/Millipore, Billerica, MA, USA).
The lower detection limit of the kit is 7.8 pg/mL of
BDNF.
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The differences between the groups at baseline were ex-
amined by analysis of variance (ANOVA) for parametric
variables with normal distribution or the Kruskal-Wallis
test, and categorical variables were examined using chi-
square or Fisher’s exact tests given that our main inde-
pendent outcome (intervention) was also categorical.
The results were evaluated using the absolute mean
variation of pain measurements quality and BDNF were
evaluating using delta values (post-treatment minus pre-
treatment). Several outcomes of pain measurements (VAS,
FIQ, PPT, number of tender points and PPT) did not
present normal distribution. Linear mixed models were
used to compare outcomes within subjects and between
subjects in which the independent variable was the treat-
ment (amitriptyline, melatonin and melatonin + amitrip-
tyline) with Bonferroni’s Multiple Comparison Test. The
reduction on the NPS(0-10) induced by the CPM-TASK
was adjusted for the baseline HPTand serum BDNF.
To identify possible predictors associated with the
change on the NPS(0-10) during the CPM-TASK, we fitted
a multiple linear regression model, using the stepwise
enter method. The variables included in the model were
as follows: B-PCS score, HPT0, and FIQ score obtained
before treatment. In addition, the number of analgesics
used in the last week of treatment was included. Finally,
an exploratory analysis using the Spearman correlation co-
efficient (rs) was performed to understand the reverse ef-
fect of the interaction of HPT0 and BDNF [each alone
presented a negative correlation with NPS(0-10) during the
CPM-TASK] that becomes positive. Within groups, the
standardized mean difference (SMD) was computed in
terms of the ratio between the mean change and the pool
of baseline standard deviation (SD). The SMD was inter-
preted as follows: small, 0.20 to 0.4; moderate, 0.50-0.70
and large, 0.80 or higher, with respective confidence inter-
val (CI) [47]. All of the analyses were performed assuming
intention-to-treat and thus included all of the randomized
subjects for whom there were observations in the study
outcomes. The analyses were performed with SPSS ver-
sion 18.0 (SPSS, Chicago, IL).
Results
Patient characteristics
The clinical and demographic characteristics of the pa-
tients are shown in Table 1. Twenty-one patients were
allocated to the amitriptyline group, 21 were allocated to
the melatonin group, and 21 patients were allocated to
the melatonin + amitriptyline group. Fifty-seven patients
completed the study; two patients in the melatonin + ami-
triptyline group and two patients in both the amitriptyline
and melatonin group withdrew because of treatment side
effects. Baseline characteristics are presented in Table 1.
The randomization produced balance groups for mostpart of characteristics, but, there was observed imbalance
between groups in pain on the VAS, FIQ and PPT
(Table 1). Regarding the side effects, in the amitriptyline
group, 38.09% (8/21) of patients presented minor side
effects (MSE) (nausea, mild dizziness, weight gain, dry
mouth, and mild headache) and 23.8% (5/21) of patients
presented major side effects (MJSE) (severe dizziness,
vivid nightmares, crippling drowsiness, severe headache,
behavioral changes, and pain worsening), with two with-
draw. In the melatonin group, 23.8% (5/21) of patients
presented MSE and 23.8% (5/21) of MJSE, with two
withdrawals. The association of melatonin + amitriptyl-
ine resulted in 14% (3/21) of patients experiencing MSE,
whereas 28.57% (6/21) of patients presented MJSE with
two withdrawals. The comparisons in the incidence of
MSE between the amitriptyline and the melatonin + ami-
triptyline group was statistically significant (P < 0.001).
However, neither the incidence of MSE nor the incidence
of MJSE was significant when the groups were compared
(P > 0.05, for all comparisons).
Analysis of the treatment effect on the main outcomes:
descending modulatory system and pain on the VAS
Patients receiving melatonin alone or in combination with
amitriptyline had significantly lower pain on the VAS than
those receiving amitriptyline alone (P < 0.01) (Figure 2). A
mixed model analysis revealed that the increase of one
supplementary analgesic dose was associated with a
5.1% increase in the adjusted VAS pain change from
baseline (t = 5.87; P < 0.001).
The change within the group was significant in all treat-
ment groups (P < 0.001, for all comparisons) (Table 2).
The cumulative mean (SD) on VAS one week pretreat-
ment vs. the pain scores in the last week of treatment in
the amitriptyline group was 62.87 (14.26) vs. 50.02 (25.60).
For the melatonin group, these values were 64.90 (15.43)
vs. 47.53 (21.96), respectively, and for the melatonin +
amitriptyline group, the values were 69.57 (9.09) vs. 48.64
(15.38)], respectively. The effect size assessed by SDM
[confidence interval (CI) 95%] within group in the ami-
triptyline group was 0.99 (CI 95%, 0.68-1.30), whereas in
the melatonin group, it was 1.29 (CI 95%, 0.98-1.58), and
in the melatonin + amitriptyline group, it was 1.47 (CI
95% 1.14-1.79) (Table 2).
The descending modulatory system function was
assessed using the CPM-TASK. It was observed that in
the overall treatment group, there was a reduction in pain
scores during the CPM-TASK: melatonin + amitriptyline
[HPT0 6.89 (1.92) vs. 4.49 (2.17) HPT1], melatonin [PPT0
7.52 (1.39) vs. 4.87 (1.97) HPT1] and amitriptyline [HPT0
6.07 (1.95) vs. 5.03 (2.17) HPT1]. The effect of treatment
on CPM is presented in Figure 3. The CPM-TASK in-
duced a reduction in pain in the melatonin group and
melatonin + amitriptyline group that was significantly
Table 1 Epidemiological and clinical characteristics at baseline, according to the treatment group, values are given as
the mean (SD) or frequency (n=63)
Amitriptyline (n = 21) Melatonin (n = 21) Amitriptyline +melatonin (n = 21) P value
Age (years) 49.80 ± (8.91) 47.40 ± (7.84) 49.72 ± (7.24) 0.59
Body index 27.65 ± (3.91) 27.18 ± (4.04) 27.58 ± (4.62) 0.60
Education (years) 10.95 ± (5.09) 11.30 ± (3.76) 8.22 + (5.6) 0.39
Smoking (n/%) 2 (9,5) 2 (9,5) 1 (5) 0.83
Clinical Comorbidity Yes/No 10 (47,6) 9 (42,9) 13 (65) 0.33
Hypertension (n/%) 5 (23,8) 5 (23,8) 8 (40)
Hypothyroidism (n/%) 3 (14,3) 1 (4,8) 7 (35)
Asthma (n/%) 1 (4,8) 1 (4,8) 2 (10)
Other (n/%) 3 (15) 0 (0) 1 (4,8)
Global pain on visual analogue scale† 62.88 ± (14.26)a 64.90 ± (15.44)a 69.57 ± (10.94)b 0.03
FIQ† 53.78 ± (12.83 )a 64.87 ± (12.83)b 65.15 ± (9.94)b 0.005
Pain catastrophizing scale for the Brazilian population (B-PCS)†
25.90 ± (10.38) 32.90 ± (12.28) 25.90 ± (10.38) 0.07
Pittsburgh Sleep Questionnaire 19.31 ± (6.58) 22.67 ± (7.69) 24.28 ± (7.79) 0.16
Hamilton Depression Scale† 17.61 ± (6.37) 21.70 ± (5.88) 17.61 ± (6.33) 0.05
Pain pressure threshold† 2.17 ± (0.21)a 1.99 ± (0.16)b 2.05 ± (0.24)a 0.04
Brain-derived neurotrophic factor (BDNF)€
Mean (SD) 48.28 ± (24.00) 52.54 ± (23.87) 48.28 ± (27.34)
Median [interquartile (IQ) 25;75] 45.51 (12.8;101.51) 54.78 (20.66;97.85 37.51 (18.75;92.3) 0.79
Psychiatric disease (SCID-I) 6 (76%) 15 (71%) 13 (65) 0.45
Depression 8 (38%) 1 (62%) 11 (55%)
Anxiety 11(52%) 12 (57%) 5 (25%)
Analgesic used weekly in last 3 months
Median (Q25-75)
€ 6 (3;28) 7 (2;26) 7 (3;29 0.91
Analgesic use: days/week in last 3 months¥
(<4 = no, ≥4 = times) 20 (95%) 20 (95%) 17 (85%) 0.43
A e aminophen/Dipirone 19 (90,5%) 16 (76,2%) 15 (75%)
NSAID 7 (33,3%) 10 (47,6%) 9 (45%)
Opioid 1 (4,8%) 0 0
Active use of central nervous system active medication¥
Yes/No 14 (66,7%) 16 (76%) 14 (70%) 0.16
Antidepressant (n/%) 14 (66,7%) 15 (71%) 13 (65%)
Anticonvulsant (n/%) 2 (9,5%) 2 (9,5%) 1 (5)
Benzodiazepine (n/%) 0 5 (23,8%) 2 (10%)
Different superscripts (a and b) indicate significant differences among treatment groups according to the Bonferroni test.
Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).
€Kruskal-Wallis Test.
¥Chi-Square or Fisher’s test.
†ANOVA.
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http://www.biomedcentral.com/2050-6511/15/40higher than in the amitriptyline group. However, it was
observed that there were patients in all treatment
groups that reported increased pain intensity (condi-
tioned pain modulation-CPM) between the HPT0 pain
measures (test stimulus) and HPT1 after the coldpressor task (CPM-TASK, conditioning stimulus). This
characterizes a summation effect, with an incidence of
15.8% (3/21) in the melatonin group, 36.8% (8/21) in
melatonin + amitriptyline group and 42% (9/21) in the
amitriptyline-treated group. These results reveal that
Figure 2 Mean pain levels as Delta value (scores on VAS (0-100 mm) in last week of treatment minus scores one week pretreatment)
in the three experimental groups. The error bars indicate the standard error of the mean. A letter b indicates a significant difference between
the melatonin group and melatonin + amitriptyline groups compared with the amitriptyline group (P < 0.05). All comparisons were performed
using a mixed analysis of variance (ANOVA) model, followed by the Bonferroni correction for post hoc multiple comparisons.
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http://www.biomedcentral.com/2050-6511/15/40the descending modulatory system lost its inhibitory
function as the heterotopy stimulus induced an increase
in pain, when a reduction would be expected [42].
To understand this result, we performed an explora-
tory analysis to identify possible factors associated with
this summation effect on pain score during the CPM-
TASK. To identify possible predictors, a multiple linearTable 2 Multivariate linear regression of the interaction
between the change in NPS (0-10) during the CPM-TASK
by the treatment group considering the BDNF and pain
thresholds (n = 63)
Parameters Β t P 95% CI
Dependent variable:
CPM-TASK
9.0 1.14 0.01 (4.33 to 32.35)
Treatment group
Melatonin + Amitriptyline -1.27 -1.72 0.09 (-2.76 to 0.21)
Melatonin -1.75 -2.5 0.01 (-3.18 to-0.31)
Amitriptyline 0b(reference)
BDNF (ng/mL) -0.28 -2.23 0.01 (-0.53 to-0.04)
Heat pain threshold -8.06 -2.49 0.01 (-14.56 to-1.55)
Interaction
Serum BDNF (ng/mL) vs.
PPT Pain pressure threshold
(Kgf/cm2)
0.12 2.07 0.04 (0.04 to 0.24)
bindicates the reference category used to do the comparisons.regression model was constructed using the stepwise
method. The variables included in the model were the
B-PCS score, HPT0, and FIQ score obtained before treat-
ment. In addition, the number of analgesics used in the
last week of treatment was included. Accordingly, the
HPT was the only variable retained in the model, that is,
associated with pain changes on NPS (0 – 10) during the
CPM-TASK [(r-square =-0.21), standard β coefficient for
the HPT =-5.99, P < 0.05)].
Thus, a mixed model was constructed to assess the ef-
fect of treatment groups and its relationship with the
serum BDNF adjusted by the HPT. It was observed that
the HPT and serum BDNF were inversely correlated
with the change on the NPS(0-10) during the CPM-TASK
(Table 3). However, when the interaction between HPT
and BDNF was analyzed, this effect changed direction
(i.e., it became positively associated with the change on
the NPS(0-10) during the CPM-TASK) (Table 3). To
understand this result, we performed a simple correl-
ation between serum BDNF and HPT, and the Spear-
man coefficient (rs) was-0.35 (P = 0.02). That is, when
the HPT0 is low (higher the pain), the serum level of
BDNF is high and vice versa. Thus, it is plausible to
suppose that the effect of this interaction (HPT*serum
BDNF) on pain score during the CPM-TASK was nega-
tively correlated when included in the model as an
isolated factor; it becomes in a factor correlated posi-
tively with the change reduction during the CPM-TASK
(Table 3).
Figure 3 Delta value on the pain NPS(0-10) during the CPM-TASK. The error bars indicate the standard error of the mean. A letter b indicates
a significant difference between the melatonin + and melatonin + amitriptyline compared with the amitriptyline group. All comparisons were
performed using a mixed analysis of variance (ANOVA) model, followed by the Bonferroni correction for post hoc multiple comparisons.
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of pain scores for FIQ score, PPT, tender points, analgesic
use, sleep quality and BDNF
The between-group changes in pain, pain threshold, anal-
gesic consumption and sleep quality are shown in Table 3.
The post hoc analysis indicated significant differences be-
tween the amitriptyline +melatonin group and the mela-
tonin group from the amitriptyline group in terms of the
FIQ score and PPT. No significant difference was ob-
served between groups in the numbers of analgesic used
in the last week of treatment, sleep quality and number
of tender points. We observed a large effect size within
groups considering the change pre- to post-treatment in
pain measures, number of tender points and sleep qual-
ity (Table 3).
Although no significant difference between treatment
groups in serum BDNF at baseline was observed, there
was large variability in the serum level of this neurotro-
phin (Table 1). From the baseline, the mean of serum
BDNF decreased 22.57% in the amitriptyline group,
whereas the melatonin group and the melatonin + ami-
triptyline group presented a mean reduction of 36.6%
and 34.49%, respectively (Figure 4). The effect size within
group as assessed by SDM in the amitriptyline group was
0.43 (CI 95%, 0.05-0.83), whereas in the melatonin
group, the value was 0.8 (CI 95%, 0.4-1.2), and in the
melatonin + amitriptyline group, the value was 0.67 (CI
95%, 0.24-1.09) (Figure 4).Discussion
The most clinically relevant finding of this study was
melatonin’s ability to improve the function of the inhibi-
tory endogenous pain-modulating system as assessed by
the reduction of the NPS(0–10) during the CPM-TASK.
In addition, this study highlights that the HPT and
BDNF serum levels at baseline were inversely correlated
with the magnitude of the treatment effect on the de-
scending modulatory system as assessed by the CPM-
TASK. Furthermore, these findings revealed that in gen-
eral, all treatments improved the FM symptoms (pain,
sleep quality); however, the clinical effect was marginally
better when the patients used melatonin alone or associ-
ated with amitriptyline.
These findings suggest that the melatonin treatment
had a direct effect on pain pathways or on the levels of
signaling chemicals that regulate pain. Melatonin induced
a reduction that was higher than 35% on the NPS(0–10)
during the CPM-TASK, and, as can be observed from the
lower limit of the confidence interval regarding pain score
on the VAS presented as SDM [1.29 (CI 95%, 0.98-1.58)],
its effect was larger than that of amitriptyline alone [0.99
(CI 95%, 0.68-1.30)]. The melatonin effect on CPM is bio-
logically plausible, and it is supported by evidence from
experimental studies about its effect on GABAergic [48],
opioid and glutamatergic systems [49]. In addition, this
hypothesis is supported by other studies that have demon-
strated a well-characterized anatomical network able to
Table 3 The mean delta score [standard deviation (SD)] (post-treatment values minus pre-treatment values) of pain
measures (FIQ, PPT, analgesic consumption, tender points) and sleep quality (n = 63)
2A. Secondary outcomes
Treatment Mean (SD) Mean difference (SD) Median of the difference
(Quartile 75;25)
P Value† SDM CI 95%
Fibromyalgia Impact Questionnaire (FIQ) score
Amitriptyline (n = 21) 41.16 (14.61) vs. 53.78 (12.83 ) -12.19 (16.27) -13.78 (-24.39,-4.95)**b 0.04 0.88 (0.43-1.33)
Melatonin (n = 21) 46.42 (16.18) vs. 64.87 (12.83) -17.73 (13.0) -16.30 (-22.29,-12.94)**b 1.28 (0.83-1.74)
Amitriptyline + melatonin (n = 21) 40.89 (10.94) vs. 65.15 (9.94) -24.65 (12.14) -26.41 (-32.59,-14.50)**a 1.79 (1.29-2.28)
b. Mean pressure pain threshold (PPT) in (kg/cm2/second)
Amitriptyline (n = 21) 2.34 (0.45) vs. 2.05 (0.24) 0.29 (0.31) 0.2 (0.1, 0.5)**b 0.03 0.69 (0.34-1.04)
Melatonin (n = 21) 2.47 (0.33) vs. 1.99 (0.16) 0.47 (0.34) 0.4 (0.23, 0.55)**b 1.13 (0.79-1.47)
Amitriptyline + melatonin (n = 21) 2.70 (0.23) vs. 2.17(0.21) 0.54 (0.60) 0.6 (0.5, 0.7)**a 1.27 (0.9-1.64)
Analgesic doses (mean during the last week of treatment)†
Amitriptyline (n = 21) 1.35 (1.2) vs. 2.07 (1.37) -0.72 (1.40) -0.22 (-0.82, 0.54)* 0.98 1.03 (0.33-1.67)
Melatonin (n = 21) 1.33 (1.29) vs. 2.16 (1.20) -0.79 (1.52) -0.14 (-1, 0.57)* 1.09 (0.51-1.66)
Amitriptyline + melatonin (n = 21) 1.04 (0.92) vs. 2.10 (1.03) -1.1 (1.14) -0.35 (-0.74, 0.47)* 1.33 (0.77-1.89)
Number of tender points
Amitriptyline (n = 21) 10.62 (3.36) vs. 14.10 (2.27) -3.45 (0.84) - 4 (-5, 1.25)** 0.89 1.99 (1.35-2.63)
Melatonin (n = 21) 10.95 (2.94) vs. 14.71 (1.70) - 3.75 (2.46) - 4 (-6.5,-2.25)** 2.17 (1.53-2.80)
Amitriptyline + melatonin (n = 21) 10.29 (3.15) vs. 14.61 (2.32) - 4.18 (1.91) - 4 (-5,-3)** 2.41 (1.72-3.10)
Pittsburgh Sleep Questionnaire
Amitriptyline (n = 21) 11.84 (5.82) vs. 19.31 (6.58) -7.47 (7.34) -7 (-11,-4)* 0.94 1.07 (0.51-1.63)
Melatonin (n = 21) 16.68 (8.38) vs. 22.67 (7.69) -6.42 (6.53) -5 (-11,-2)* 0.9 (0.38-1.44)
Amitriptyline + melatonin (n = 21) 16.11 (8.40) vs. 24.28 (7.79) -7.58 (1.91) -8 (-12,-1.5)* 1.06 (0.52-1.59)
*P < 0.01, **P < 0.0001 Comparisons using Mixed ANOVA model.
†Mixed ANOVA model. Mean difference of group. Different superscripts (a, b, and c) indicate significant differences among treatment groups according to the
Bonferroni test.
Standardized mean difference (SMD) [(pre minus post)/pool baseline standard deviation] with confidence interval (CI) 95%. The size effect was interpreted as
follows: small, 0.20 to 0.40; moderate, 0.50-0.70; and large, 0.80 or higher.
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horn) in various circumstances to produce either facilita-
tion (pronociception) or inhibition (antinociception) [50].
Therefore, melatonin may also inhibit the descending
pathways that facilitate pain transmission, which are be-
lieved to be circuits with a sustained activation that under-
lies chronic pain, such as in FM [51,52]. Overall, these
findings suggest that melatonin increased the inhibitory
descending pain system effect, which involves anatomical
connections between cortical and brainstem regions in the
human brain, as demonstrated by tractography [53].
The inverse correlation between CPM-TASK, BDNF
and HTT0 (Table 2) corroborates the presence of central
sensitization theory, which is related to a reduction in
the descending inhibitory system activity [54] and to a
greater activation in the brainstem [55]. Thus, the reduc-
tion of BDNF suggests that this neuromodulator is in-
volved in central sensitization [56,57]. This neurotrophin
is involved in altering the excitatory/inhibitory balance
in the central nervous system (CNS) and in the amplifi-
cation of pain response [58,59]. Because BDNF levelscan serve as a molecular “sensor” of the global levels of
neuronal activity, it has been suggested that the induc-
tion of BDNF expression in response to increases in the
level of neuronal activity may dampen cortical excitabil-
ity by promoting the development and/or strengthening
of inhibitory synapses in local circuits [60,61]. This
multifaceted mechanism of melatonin’s effect on pain
also results in a reduction in serum BDNF, an effect ob-
served in this study, which corroborates the results of a
previous randomized clinical trial concerning chronic
pelvic pain induced by endometriosis [16].
In addition, melatonin’s effect on BDNF observed in
this study may be explained by its anti-inflammatory
effects. This hypothesis is supported by the relation be-
tween BDNF and pro-inflammatory cytokines that has
been demonstrated in FM patients [62-64]. Melatonin
has marked anti-inflammatory effects on peripheral sites
by inhibiting the release of pro-inflammatory cytokines
[12]. Additional mechanisms involved in melatonin’s ef-
fect on pain pathways include an important reduction of
nitric oxide (NO) and malondialdehyde (MDA) levels,
Figure 4 Mean serum BDNF (ng/mL) at baseline and the after treatment presented as the mean ± SEM. The asterisk indicates a significant
within group difference according to Mixed ANOVA model with Bonferroni test. Delta values (serum BDNF before treatment minus serum BDNF
after pretreatment) were performed using a Mixed ANOVA. The error bars indicate the standard error of the mean. aIndicates that the treatment
did not induce an effect that was significantly different between treatment groups (P > 0.05).
de Zanette et al. BMC Pharmacology and Toxicology 2014, 15:40 Page 11 of 14
http://www.biomedcentral.com/2050-6511/15/40two compounds that are closely related to inflammation
[65]. Melatonin inhibits the inflammatory response and
inducible NO synthase (iNOS) isoform expression [66],
as demonstrated in FM patients by Citera et al. [5]. In
addition, melatonin as an adjuvant of drugs that increase
serotonin (e.g., SSRIs, tricyclic antidepressants) could be
a beneficial pharmacological approach for the manage-
ment of patients with FM [6]. Overall, these findings re-
veal that melatonin may change a response associated
with a maladaptive neuroplasticity process orchestrated by
neuronal, endocrinal, and immune mechanisms that can
amplify sensory pain signals to the neural pain matrix.
The present study demonstrated that all treatments
reduced pain, and in the melatonin-treated groups, this
effect was marginally better than in the amitriptyline
group. Melatonin’s effect on pain was demonstrated by
the VAS, FIQ and PPT. These findings corroborate evi-
dence of experimental studies [8] and previous random-
ized clinical trials on acute pain [10,14] and chronic pain
such as fibromyalgia [5,6], temporomandibular disorders
[15], endometriosis [16] and a dose–response study with
healthy subjects [26]. The highly lipid-soluble nature of
melatonin allows it to easily penetrate the blood–brain
barrier. The antinociceptive effect of melatonin is known
to involve the activation of supraspinal sites and the in-
hibition of “spinal windup” [67,68].
Evidence from experimental studies suggests that the
analgesic effects of melatonin are mediated by opioids
[69] and by gamma-aminobutyric acid ([GABA] ergic)systems [27,28], but it is not possible to dissociate the
effect of each individual neurobiological system in hu-
man experimental and clinical studies. Indeed, only the
net effect can be assessed. Studies have also suggested
that additional pathways play a role in the analgesic
actions of melatonin, such as the nuclear signaling path-
ways, receptor-independent radical scavenging, and in-
hibition of the release of pro-inflammatory cytokines at
peripheral sites.
According to previous clinical studies, the most preva-
lent complaints in patients with FM were sleep disturb-
ance, fatigue, and chronic pain, and these symptoms
might be a consequence of melatonin secretion disrup-
tion [70]. Moreover, serum levels of melatonin precur-
sors (tryptophan and serotonin) have been reported to
be low in patients with FM [71,72]. This could explain the
lack of restorative sleep and could be a mechanism in-
volved in dysfunctional pain modulation [3]. Thus, the re-
storing of melatonin could be an additional mechanism
among the others not yet discussed to explain the discrep-
ancy of its effect compared with amitriptyline. However,
one can realize that, overall, the association with ami-
triptyline induced only a marginal increase in the
clinical effect. This finding is contrary to our initial hy-
pothesis that the combined treatment (melatonin + ami-
triptyline) might provide an effect with a higher clinical
impact. Although the interventions were randomly allo-
cated to balance the characteristic between arms, some
baseline pain traits were higher in group that received
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chance, but the random allocation ensures the groups
were not systematically biased [73]. Furthermore, if any
disadvantage would appear, it would be on this group
(i.e. amitriptyline + melatonin) which had more clinical
comorbidities. Accordingly, our findings highlight that
melatonin alone or in combination with amitriptyline
might improve the efficacy of fibromyalgia treatment in
those with more severe symptoms. This finding is in ac-
cordance with a recent study that demonstrated an as-
sociation between lower levels of 6-sulfatoxy-melatonin
with higher severe symptoms of FM such as pain, sleep
disturbances, fatigue, anxiety and depression [74]. How-
ever, to reduce the possible influence of this imbalance
in the treatment effect, all analyses were fitted using the
delta value of the outcomes from baseline. In addition,
these results also agree with previous studies that dem-
onstrate that antidepressant drugs (selective serotonin
reuptake inhibitors, SSRIs) associated with melatonin-
improved fibromyalgia symptoms [6].
The strengths of this study include the comparison of
melatonin and amitriptyline association in a phase II,
randomized, double-dummy factorial design, placebo-
controlled trial and the use of multiple efficacy and safety
measures based on previous trial experience. Although
the important effects of SSRIs in FM are well known, the
effects of the association of melatonin and amitriptyline in
this chronic pain condition were not previously studied.
We conducted this trial according to CONSORT guide-
lines, and given that we used the Delphi List (a list of cri-
teria for the quality assessment of randomized controlled
trials), our randomized controlled trial can be considered
to be of strong quality because all 8 items in this scale can
be positively scored [75]. In addition, we used the double-
dummy method and shield placement to prevent the
patient and team members from following the patients to
control assessment bias. These findings are important be-
cause they demonstrate that the application of new thera-
peutics can be assessed in each particular context to
determine whether they provide enough benefit over those
already available [76]. The factorial design is a proposed
method for examining the interactions between treat-
ments by generating an interaction ratio. In addition, this
method permits us to estimate whether the “at the mar-
gins” analyses may have overestimated or underestimated
the efficacy (and adverse effects) of each agent. A potential
limitation is the short treatment duration, but it would
have been difficult to justify a prolonged treatment period
in patients experiencing chronic pain if they had a high in-
cidence of severe side effects. Accordingly, the incidence
of MJSE in the amitriptyline group was 38.09%. This find-
ing is in accordance with the literature reporting that the
tricyclic antidepressants are effective at alleviating pain
and improving sleep quality [77]; however, the complaintsrelated to common anticholinergic side effects such as dry
mouth, sedation, constipation, orthostasis and weight gain
are common [78]. We emphasize that the results of this
study are relevant only to the patient population investi-
gated. Although the homogeneity of this study population
is methodologically advantageous, the issue of external
validity arises. Thus, additional research with a larger
number of patients is needed to more widely assess the
potential benefits of melatonin in several different clinical
settings, and future studies are required before definitive
conclusions regarding melatonin and pain treatment can
be made. Finally, although several strategies were used to
prevent patients and the evaluator team from unblinding,
formal assessment for awareness of the allocation (either
active or placebo) was not performed. However, our ob-
jective surrogates less prone to bias (i.e., serum BDNF, an-
algesics requirements, CPM-TASK) were consistent with
pain scores, and thus, unblinding is unlikely to have influ-
enced the direction of our conclusions.Conclusion
In conclusion, in this 6-week, randomized, double-dummy,
placebo-controlled study, melatonin alone or associated
with amitriptyline was better than amitriptyline alone in
improving pain on the VAS, FIQ and PPT, whereas its
association with amitriptyline produced only marginal
additional clinical effects. Melatonin increased the inhibi-
tory endogenous pain-modulating system as assessed by
the reduction of the NPS(0-10) during the CPM-TASK. In
addition, this study suggests that peripheral BDNF could
be used as a biomarker of central sensitization, as it is in-
versely correlated with pain reduction in the CPM-TASK.
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